Expansion of antibacterial agents into emerging markets and metal caps for medical applications
First written in FY2016. 13 of 33 entries say "Restated". Latest entry: 2026-10-22.
No other company in this theme has enough history to compare yet.
- 2026-10-22WorsenedEarnings
「抗菌剤は、原材料価格の高騰に伴う販売価格の改定等により出荷量が減少しました。」
原材料価格高騰への価格改定に伴い、抗菌剤の出荷量減少が記載された。 - FY2026Shift from declining shipments to strengthening cost competitivenessAnnual report
「For antimicrobial agents, the company is continuing to develop sales channels in the markets for molded resin products and textiles, while accelerating the development of cost-competitive formulations to address the decline in market competitiveness caused by price revisions accompanying higher raw-material costs.」
The company is broadening its focus beyond price revisions in response to higher raw-material prices to developing cost-competitive formulations as a way to address the decline in market competitiveness caused by those price revisions. - 2026-04-23AdvancedEarnings presentation
「抗菌剤・防錆剤のほか、新たなニーズに応える機能材料の製品開発を推進。自動車関連、医療関連等の新たな用途、グローバルでの新たな地域への展開により需要の開拓に注力。」
抗菌剤等について、従来の海外展開に加えて自動車・医療などの新用途と新地域を開拓する方向を具体化している。 - FY2026-H1Antimicrobial-agent sales increase through price adjustmentsAnnual report
「Sales increased as the company revised selling prices in response to higher raw-material prices.」
Compared with previous references centered on expanding overseas demand, the company states that during the first half, selling-price revisions in response to higher raw-material prices contributed to increased sales of antimicrobial agents. - FY2025-Q1RestatedAnnual report
「As shipments of antimicrobial agents approached pre-pandemic levels and selling prices were revised in response to higher raw-material prices, sales for the segment as a whole reached ¥1,142 million, up 1.2% year on year.」
The company continues to report that shipments of antimicrobial agents are approaching pre-pandemic levels and that selling prices have been revised in response to higher raw-material prices. - FY2024ReframedAnnual report
「The company will establish systems to respond to changes in the market and develop new antimicrobial agents for which demand is expected.」
The focus of the antimicrobial-agent business is shifting from expansion of overseas demand alone to establishing systems that respond to post-pandemic market changes and developing new antimicrobial agents. - FY2024-Q3RestatedAnnual report
「As the impact of COVID-19 subsided and global prices rose, strong demand for antimicrobial agents in overseas markets eased, and shipments returned to pre-pandemic levels. Shipments of metal caps for both alcoholic beverages and pharmaceuticals increased, but sales for the segment as a whole reached ¥3,764 million, down 1.6% year on year.」
The company reconfirms that overseas demand for antimicrobial agents has returned to pre-pandemic shipment levels, while shipments of metal caps for alcoholic beverages and pharmaceuticals have increased. - FY2024-Q2RestatedAnnual report
「As the impact of COVID-19 subsided and global prices rose, strong demand for antimicrobial agents in overseas markets eased, and shipments returned to pre-pandemic levels. Shipments of metal caps for alcoholic beverages increased, but sales for the segment as a whole reached ¥2,394 million, down 11.9% year on year.」
The company reconfirms that overseas demand for antimicrobial agents has returned to pre-pandemic shipment levels and that shipments of metal caps for alcoholic beverages have increased. - FY2024-Q1Overseas demand for antimicrobial agents returns to pre-pandemic shipment levelsAnnual report
「As the impact of COVID-19 subsided and global prices rose, strong demand for antimicrobial agents in overseas markets eased, and shipments returned to pre-pandemic levels. Shipments of metal caps for both alcoholic beverages and pharmaceuticals increased, but sales for the segment as a whole reached ¥1,128 million, down 13.7% year on year.」
Strong overseas demand for antimicrobial agents eased, and shipments returned to pre-pandemic levels. Meanwhile, shipments of metal caps for alcoholic beverages and pharmaceuticals increased. - FY2023-Q3RestatedAnnual report
「Shipments of antimicrobial agents remained sluggish as strong overseas demand eased. Shipments of metal caps for both alcoholic beverages and pharmaceuticals were broadly in line with the previous year, and sales for the segment as a whole reached ¥3,825 million (year-on-year change: -%).」
The company reconfirms the sluggish shipments of antimicrobial agents due to easing overseas demand and the broadly year-on-year level of metal-cap shipments for alcoholic beverages and pharmaceuticals. - FY2023-Q1Overseas demand eases and supply stagnates due to urban lockdowns in ChinaAnnual report
「Shipments of antimicrobial agents remained sluggish as strong overseas demand eased and supply chains stagnated due in part to urban lockdowns in China. Shipments of metal caps for both alcoholic beverages and pharmaceuticals were roughly in line with the previous year, and sales for the segment as a whole reached ¥1,307 million (year-on-year change: -%).」
Shipments of antimicrobial agents remained sluggish as overseas demand eased, compounded by supply-chain stagnation caused by urban lockdowns in China. - FY2022-Q3AdvancedAnnual report
「Amid the impact of COVID-19, demand for antimicrobial agents remained strong, particularly in overseas markets, as it had since the previous year, driving sales growth. Shipments of metal caps for both alcoholic beverages and pharmaceuticals remained sluggish, and sales for the segment as a whole reached ¥4,041 million, up 17.8% year on year.」
Sales of antimicrobial agents continued to expand, particularly on strong demand in overseas markets, resulting in a 17.8% year-on-year increase in sales for the Other business. Meanwhile, shipments of metal caps for alcoholic beverages and pharmaceuticals remain sluggish. - FY2022-Q2AdvancedAnnual report
「Amid the impact of COVID-19, demand for antimicrobial agents remained strong in both the domestic and overseas markets, as it had since the previous year, driving sales growth. Shipments of metal caps for both alcoholic beverages and pharmaceuticals remained sluggish, and sales for the segment as a whole reached ¥2,694 million, up 22.8% year on year.」
Sales of antimicrobial agents continued to expand on strong domestic and overseas demand, resulting in a 22.8% year-on-year increase in sales for the Other business. Meanwhile, shipments of metal caps for alcoholic beverages and pharmaceuticals remained sluggish. - FY2022-Q1AdvancedAnnual report
「Demand for antimicrobial agents remained strong in both the domestic and overseas markets, driving sales growth. Shipments of metal caps for both alcoholic beverages and pharmaceuticals remained sluggish, and sales for the segment as a whole reached ¥1,380 million, up 19.8% year on year.」
Strong domestic and overseas demand for antimicrobial agents continued to drive sales growth, resulting in a 19.8% year-on-year increase in sales for the Other business as a whole. Meanwhile, shipments of metal caps for alcoholic beverages and pharmaceuticals remained sluggish. - FY2021AdvancedAnnual report
「The company will establish production and sales systems in preparation for the post-pandemic environment, enhance new product lines including high-performance antiviral agents, and pursue market development.」
In response to increased demand for antimicrobial agents, the company newly outlined plans to enhance new product lines, including antiviral agents, and establish production and sales systems. - FY2021-Q3AdvancedAnnual report
「Sales of antimicrobial agents expanded, particularly as demand increased substantially in overseas markets. Orders for metal caps for pharmaceuticals also increased, and sales for the segment as a whole reached ¥3,431 million, up 28.0% year on year.」
Demand for antimicrobial agents increased particularly in overseas markets, while orders for metal caps for pharmaceuticals also increased, resulting in a 28.0% year-on-year increase in sales for the Other business. - FY2021-Q2AdvancedAnnual report
「Sales of antimicrobial agents expanded as demand increased in the domestic and overseas markets. Shipments of metal caps were broadly in line with the previous fiscal year, and sales for the segment as a whole reached ¥2,194 million, up 15.7% year on year.」
Sales of antimicrobial agents expanded on higher demand in the domestic and overseas markets, and sales for the Other business increased 15.7% year on year. - FY2021-Q1AdvancedAnnual report
「Sales of antimicrobial agents expanded as demand increased substantially in both the domestic and overseas markets. Shipments of metal caps were broadly in line with the previous fiscal year, and sales for the segment as a whole reached ¥1,152 million, up 21.8% year on year.」
Demand for antimicrobial agents increased substantially in both the domestic and overseas markets, resulting in a 21.8% year-on-year increase in sales for the Other business as a whole. - FY2020Decline in domestic and overseas sales extends to the full yearAnnual report
「Sales of antimicrobial agents declined in both the domestic and overseas markets. Shipments of metal caps for pharmaceuticals also remained sluggish, and sales for the segment as a whole reached ¥3,561 million, down 10.9% year on year.」
Even for antimicrobial agents, for which the company had been pursuing overseas sales-channel expansion, sales declined in both the domestic and overseas markets during the year, resulting in a 10.9% year-on-year decline in sales for the Other business as a whole. - FY2020-Q3Decline in domestic and overseas sales becomes apparentAnnual report
「Sales of antimicrobial agents declined in both the domestic and overseas markets. Shipments of metal caps for pharmaceuticals also remained sluggish, and sales for the segment as a whole reached ¥2,681 million, down 11.9% year on year.」
In contrast to previous references to the expansion of overseas sales channels for antimicrobial agents, sales declined in both the domestic and overseas markets this quarter. Shipments of metal caps for pharmaceuticals also remained sluggish. - FY2020-Q2RestatedAnnual report
「Sales channels for antimicrobial agents expanded in overseas markets, but sales in Japan and to China declined. Shipments of metal caps for pharmaceuticals also remained sluggish, and sales for the segment as a whole reached ¥1,897 million, down 8.5% year on year.」
Expansion of overseas sales channels for antimicrobial agents continued, while declining sales in Japan and to China coincided with sluggish shipments of metal caps for pharmaceuticals. - FY2020-Q1Expansion of sales channels alongside declining sales in China and to OEM customersAnnual report
「Sales channels for antimicrobial agents expanded steadily in Japan and overseas, but sales in China and to OEM customers declined. Shipments of metal caps for pharmaceuticals also remained sluggish, and sales for the segment as a whole reached ¥946 million, down 13.3% year on year.」
Domestic and overseas sales channels for antimicrobial agents continued to expand, while sales in China and to OEM customers declined, resulting in a 13.3% year-on-year decline in sales for the Other business as a whole. - FY2019-Q3RestatedAnnual report
「Sales of antimicrobial agents expanded steadily in Japan and overseas. Meanwhile, shipments of metal caps for pharmaceuticals remained sluggish, but sales for the segment as a whole reached ¥3,044 million, up 1.9% year on year.」
The company reconfirms the expansion of domestic and overseas sales of antimicrobial agents and the sluggish shipments of metal caps for pharmaceuticals. - FY2019-Q2RestatedAnnual report
「Sales of antimicrobial agents expanded steadily in Japan and overseas. Meanwhile, shipments of metal caps for pharmaceuticals remained sluggish, but sales for the segment as a whole reached ¥2,073 million, up 6.1% year on year.」
The company reconfirms the expansion of domestic and overseas sales of antimicrobial agents and the sluggish shipments of metal caps for pharmaceuticals. - FY2019-Q1RestatedAnnual report
「Sales of antimicrobial agents expanded steadily in Japan and overseas. Meanwhile, shipments of metal caps for pharmaceuticals remained sluggish, but sales for the segment as a whole reached ¥1,091 million, up 9.1% year on year.」
The company reconfirms the expansion of domestic and overseas sales of antimicrobial agents. Shipments of metal caps for pharmaceuticals remained sluggish, but sales for the Other category as a whole increased 9.1% year on year. - FY2018RestatedAnnual report
「As the domestic market for antimicrobial agents is in a mature phase, the company is expanding its sales channels by targeting overseas markets. It will address challenges including tighter regulations on chemical substances and the UK's withdrawal from the EU, and will propose proactive sales activities.」
The company reconfirms its plans to expand overseas sales channels for antimicrobial agents and respond to regulations and the UK's withdrawal from the EU. - FY2018-Q3AdvancedAnnual report
「Sales of antimicrobial agents expanded steadily overseas, particularly in Asia and Europe. Shipments of metal caps and other products also increased, with sales reaching ¥2,989 million, up 11.9% year on year.」
The expansion of overseas sales of antimicrobial agents, including in Asia and Europe, and increased shipments of metal caps and other products continued, with sales for the Other category up 11.9% year on year. - FY2018-Q2RestatedAnnual report
「Sales of antimicrobial agents expanded steadily overseas, particularly in Asia and Europe. Shipments of metal caps for alcoholic beverages and pharmaceuticals also remained solid, with sales reaching ¥1,954 million, up 11.0% year on year.」
The company reconfirms the expansion of overseas sales of antimicrobial agents, including in Asia and Europe, and the solid performance of metal-cap shipments for alcoholic beverages and pharmaceuticals. - FY2018-Q1RestatedAnnual report
「Sales of antimicrobial agents expanded steadily in Japan and overseas. Meanwhile, shipments of metal caps for alcoholic beverages remained sluggish, but sales for the segment as a whole reached ¥1,000 million, up 6.1% year on year.」
The company reconfirms the expansion of domestic and overseas sales of antimicrobial agents. Shipments of metal caps for alcoholic beverages remained sluggish, but sales for the Other segment as a whole increased 6.1% year on year. - FY2017RestatedAnnual report
「As the domestic market for antimicrobial agents is in a mature phase, the company needs to expand its sales channels by targeting overseas markets. It will address challenges including tighter regulations on chemical substances and the UK's withdrawal from the EU, and will further expand its sales channels. For metal caps, it will work to secure appropriate profits through rigorous cost control and stable supplies by maintaining and improving quality.」
The company continues to target expansion of overseas sales channels for antimicrobial agents, responses to regulations and the UK's withdrawal from the EU, and cost and quality control for metal caps. - FY2017-Q3RestatedAnnual report
「Sales of antimicrobial agents expanded steadily in Europe and the United States, but sales were roughly flat year on year due in part to the reaction to large orders received as adoption expanded in certain regions last year. Meanwhile, shipments of metal caps and other products increased, with sales reaching ¥2,670 million, up 2.7% year on year.」
The company reconfirms the expansion of antimicrobial-agent sales in Europe and the United States and increased shipments of metal caps and other products, while sales of antimicrobial agents remained roughly flat year on year. - FY2017-Q2AdvancedAnnual report
「Sales of antimicrobial agents overseas, particularly in Europe, are expanding steadily, but revenue declined due in part to the reaction to large orders associated with expanded adoption in certain regions last year. Meanwhile, shipments of metal caps and other products increased, resulting in revenue of ¥1,759 million, up 1.7% year on year.」
Overseas sales of antimicrobial agents expanded, including in Europe, while shipments of metal caps and other products also increased. However, sales of antimicrobial agents declined due to the reaction to large orders received in the previous year. - FY2016First statedAnnual report
「In the antimicrobial agents business, the company will pursue the performance and cost levels demanded by the market and expand into emerging markets. For metal caps, it will promote sales activities that accurately capture market changes in the healthcare sector, including the rise of generic drugs.」
The company cites performance, cost and emerging markets for antimicrobial agents, and responding to market changes in the healthcare sector for metal caps.